HLA(Human Leucocyte Antigen)That is, human leukocyte antigen, encoded by the gene complex located on the short arm of human chromosome 6, is the most complex genetic polymorphism system currently known. It is expressed on the surface of human cell membrane and represents the antigen specificity of each individual. HLA is closely related to the immune system of the body and is the main antigen that mediates graft rejection.

Product introduction

HLA is the main antigen that mediates graft rejection, and the graft survival depends largely on the extent to which the donor and the recipient are compatible with the HLA type. At present, our company is mainly through the technology of PCR- sequence specific primers (squence specific, primer, PCR-SSP) and PCR- direct sequence analysis of genotyping technology (sequence based genotyping, PCR-SBT) two kinds of methods to judge the degree of consistency for both sides, for the clinical diagnosis, providing guidance and treatment of transplantation.

HLA分型产品流程

What are the advantages of HLA typing and previous analytical means?

Serological typing is a simple and rapid method. The disadvantage is that the typing rate is very low, sometimes it is not easy to get the relevant typing serum, and it can not ensure the true match of HLA between the donor and the patient. Now it's basically the molecular biology, and the PCR-SSP or PCR-SBT methods are commonly used. The detection method has a qualitative leap in detecting flux, data quality and cost control, and high resolution database is not only conducive to finding the right donor quickly and accurately, but also greatly improving the utilization rate of bone marrow bank.

Product use:

The application of donors before transplantation of hematopoietic stem cells, kidney, heart and other organs, bone marrow bank, and the establishment of the umbilical blood bank

Sampling notes

Requirement:

1. required blood volume: normal 2ml, patient 3-5ml. (anticoagulant ACD or EDTA or CPDA).

2. after collecting blood, the anticoagulant and blood were mixed.

The 3. sample tube should be marked with the name of the blood sample and the date of collecting blood. If a number of samples are collected, a unique marker is marked on each sample tube so as not to be confused.

Suggestion:

There was no large amount of blood transfusion in the first 10 days of the 1. type, and no chemotherapy and chemotherapy were done.

2. of the parents were typed at the same time.

3. no heparin anticoagulant was used.

Report cycle: 5-7 working days (telephone contact for special cases)